Onkologie 2020: 14(Suppl.E): 119-121 | DOI: 10.36290/xon.2020.069
Case report of a young patient with a massively disseminated malignant melanoma treated with targeted therapy
- 1 Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno
- 2 Oddělení nukleární medicíny, Masarykův onkologický ústav, Brno
- 3 Lékařská fakulta Masarykovy univerzity, Brno
Disseminated malignant melanoma is an aggressive disease and, despite the advancement in treatment modalities, it is still one of the diseases with an unfavorable prognosis. We present a case report of a patient with a rapidly-progressing disseminated skin melanoma treated with targeted therapy using dabrafenib and trametinib. The treatment was tolerated well and provided the patient with a very rapid symptom relief. Unfortunately, despite the initial rapid response, the disease progressed after less than five months. The case report demonstrates that targeted treatment is effective even in very advanced and symptomatic diseases, but it is necessary to take into account the fact that its effect is temporary. These patients can find hope in a combination with modern immunotherapy, the results of which are being expected.
Keywords: melanoma, targeted therapy, dabrafenib, trametinib, case report.
Published: September 25, 2020 Show citation
| ACS | AIP | APA | ASA | Harvard | Chicago | Chicago Notes | IEEE | ISO690 | MLA | NLM | Turabian | Vancouver |
References
- Liu C, Peng W, Xu C, et al. BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice. Clin Cancer Res 2013; 19: 393-403.
Go to original source... 
Go to PubMed... - Tawbi HAH, Amaria RN, Glitza IC, et al. Safety and preliminary activity data from a single center phase II study of triplet combination of nivolumab (N) with dabrafenib (D) and trametinib (T) [trident] in patients (Pts) with BRAF-mutated metastatic melanoma (MM). J Clin Oncol 2018; 36: 9560-9560. Go to original source...
- A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma; NCT02908672.
- Dummer R, Schadendorf D, Nathan P, et al. Abstract CT182: The anti-PD-1 antibody spartalizumab (PDR001) in combination with dabrafenib and trametinib in previously untreated patients with advanced BRAF-V600-mutant melanoma: first efficacy, safety, and biomarker findings from the part 2 biomarker cohort of COMBi-i. Cancer Res 2018; 78: CT182-CT182. Go to original source...
- Ascierto PA, Ferrucci PF, Stephens R, et al. KEYNOTE-022 Part 3: phase 2 randomized study of 1L dabrafenib (D) and trametinib (T) plus pembrolizumab (pembro) or placebo (PBO) for BRAF-mutant advanced melanoma. Ann Oncol 2018; 29: 442-466. Go to original source...
- Das Thakur M, Salangsang F, Landman AS, et al. Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 2013; 494: 251-255. Go to original source... Go to PubMed...
- Algazi AP, Othus M, Daud A, et al. SWOG S1320: a randomized phase II trial of intermittent versus continuous dosing of dabrafenib and trametinib in BRAFV600E/k mutant melanoma. J Clin Oncol. 2015; 33 TPS9093-TPS9093. Go to original source...